article
Cancer metastasis: breakthrough in therapeutic strategies
A new discovery from the University of Southern California (USC) on cancer metastasis has opened up new possibilities for combating the spread of this devastating disease.
List view / Grid view
Cancer
podcasts
Episode 21 – Allogeneic cell therapies and the immune system
This episode defines allogeneic cell therapy as the administration of cells to a patient for therapeutic use, that were not initially taken from that patient.
news
Cracking the code of influenza evolution
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
news
Harnessing machine learning for early cancer detection in primary care
Machine learning (ML) presents a promising opportunity to revolutionize early cancer detection in primary care, addressing the challenges associated with diagnostic errors and improving patient outcomes. The potential of ML in this field is highlighted in a recent paper published in Oncoscience
news
Specialised white blood cells could lead to more preventative treatments
Australian researchers analyse the way specialised white blood cells produce an immune response, which could lead to the development of preventative treatments for cancer and infectious diseases.
article
Biochemical assays and deep cyclic inhibition in cancer treatment
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.
article
The promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
article
Antibody Drug Conjugates: windows of opportunity
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…
article
T cells’ vital role in boosting immune responses
In this article, Drug Target Review's Izzy Wood uncovers the cutting-edge breakthroughs in T cell research that are revolutionising our understanding of the immune system and paving the way for new therapies and treatments.
news
3D bioprinting artificial organs could become quicker and easier
Novel 3D bioprinting process could save thousands of lives by streamlining the creation of tissue-compatible artificially engineered organs.
article
Game-changing pan-TEAD inhibitor for solid tumours
Insilico Medicine has announced the nomination of ISM6331 as a potential best-in-class pan-TEAD inhibitor for the treatment of advanced solid tumours.
article
Neoantigen-directed cancer treatment
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, explores research on T-cell therapy for cancer, which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
article
Chemotherapy-free treatment for patients with blood cancer
Dr Andy Souers highlights the unwavering commitment to finding an enhanced therapeutic approach that eliminates the need for chemotherapy in blood cancer treatment. This transformative discovery represents a significant leap forward in the way we combat this complex disease, offering new hope to countless patients worldwide.
article
Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
In this article Dr Raymond Winquist, Oncology Fellow at Alkermes, covers the longstanding research challenges associated with cytokines: IL-12 and IL-18, and their untapped potential in immunotherapy and immuno-oncology.
article
Breakthrough drug candidates and cancer treatment innovations
In this exclusive interview with Dr Paul Moore, Chief Scientific Officer from Zymeworks, we explore the impressive responses of Zymeworks' antibody-drug conjugate ZW191 in FRα-low expressing models, indicating its efficacy in treating various oncology indications.
